公司业务发展 - 公司是一家创新的合成生物学和基因组学公司，开发了可扩展的DNA合成平台，以实现生物工程的工业化[92] 收入增长 - 公司在2023年3月31日的三个月内实现了6002万美元的收入，同比增长25%，主要是由于NGS工具、合成基因和寡核苷酸池订单增长，特别是在医疗保健领域[96] - 公司在2023年3月31日的三个月内净收入从2022年12月31日的5420万美元增加至6020万美元，主要是由于美洲和EMEA地区大客户订单增加，APAC地区收入增长主要是由于中国经济复苏和日本季节性销售增长[98] - 公司在2023年3月31日的三个月内服务了约2100名客户，与2022年同期相比，收入增长至6020万美元，主要是由于美洲和EMEA地区大客户订单增加，APAC地区收入增长主要是由于中国经济复苏和日本季节性销售增长[98] - 公司在2023年3月31日的三个月内合成基因收入增至1801.1万美元，主要是由于合成生物和学术研究行业的扩张以及产品周转时间的改善[107] - 公司在2023年3月31日的三个月内NGS工具收入增至2894万美元，主要是由于大客户的增长和医疗保健和工业化学品行业的增长[107] - 2023年3月31日，营收为1.14423亿美元，同比增长27%[113] 财务状况 - 2023年3月31日，研发费用为2,737.9万美元，同比下降12%[109] - 2023年3月31日，销售、总务和行政费用为5,396.5万美元，与去年同期持平[110] - 2023年3月31日，持有的现金及现金等价物为3.152亿美元[122] 现金流 - 2023年3月31日，投资活动净现金流为3,418.9万美元[126] - 在2022年3月31日结束的六个月中，公司的投资活动使用了净现金2.399亿美元[127] - 在2023年3月31日结束的六个月中，公司的融资活动提供了净现金1.1百万美元[129] - 在2022年3月31日结束的六个月中，公司的融资活动提供了净现金2.706亿美元[130]

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and ESG Officer Emily Leproust - CEO and Co-Founder James Thorburn - CFO Conference Call Participants Vijay Kumar - Evercore ISI Matt Larew - William Blair Steven Mah - Cowen Sung-Ji Nam - Scotiabank Luke Sergott - Barclays Puneet Souda - SVB Securities Tom Peterson - Baird Rachel Vatnsdal - JPMorgan Operator Good morning, ladies and gentlemen, and w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 (State or othe ...

Twist Bioscience Corp (NASDAQ:TWST) Q1 2023 Earnings Conference Call February 3, 2023 8:00 AM ET Company Participants Angela Bitting - Chief ESG Officer & SVP, Corporate Affairs Emily Leproust - Co-Founder, Chairman & CEO James Thorburn - CFO Conference Call Participants Poon Mah - Cowen and Company Luke Sergott - Barclays Bank Matthew Larew - William Blair & Company Vijay Kumar - Evercore ISI Puneet Souda - SVB Securities Noah Burhance - JPMorgan Chase & Co. Operator Welcome to Twist Bioscience's Fiscal 20 ...

Fiscal 2022 4Q and Year-End Financial Results 1 Agenda Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Quarterly and Annual Highlights Emily Leproust Chief Executive Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Pipeline & Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | T W I S T B I O S C I E N C E Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements of historical facts contained ...

GAGATCTA ATCGATT I C G A T LT W BIOSCIENCE Writing the Future AUGUST 2022 AGATCTAGCGAT G G A T C C T A C G T A C A TCATGAGATTCAGGATTCATGCTGC - Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forwardlooking statements reflecting the current beliefs and expectations of management and include statements regarding, among other things, future financial performance, expectations and objectives of manage ...

G A G A G A L C T A ATCGATTS ICGAIA TGAGATCI W Fiscal 2022 3Q Financial Results AGATCTAG CGAT GATCOSTAGGTACAO ATGAGA TCATGAGATCCAGGATTCATGCTGC Agenda Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Quarterly Highlights Emily Leproust Chief Executive Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Pipeline & Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE i- Legal Disclaimers This presentation contains forward-looking stat ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | LOREM IPSUM | | | | | | DOLOR SIT AMET CONSECTETUR Twist Advances in NGS Applications Emily Leproust, PhD CEO and Co-Founder | | | | | | | | | | | 1 Legal Disclaimers This presentation contains forward-looking statements. In particular, statements regarding Twist Bioscience Corporation's ("Twist," "we ...

GAGAIICTA ATCGATTS ICGAIA TGAGATCI W BIOSCIENCE Fiscal 2022 2Q Financial Results AGATCTAG CGAT GATCC CTACACACATGAGA TCATGAGATCCGATTCATGCTGC Agenda Welcome Angela Bitting SVP, Corporate Affairs Quarterly Highlights Emily Leproust Chief Executive Officer Financial and Operational Performance Jim Thorburn Chief Financial Officer Pipeline & Milestones Emily Leproust Chief Executive Officer Q&A Session 2 | TWIST BIOSCIENCE i- Legal Disclaimers This presentation contains forward-looking statements. All statements ...

GAGATCTA ATCGATT I C G A T LT W BIOSCIENCE Writing the Future FEBRUARY 2022 AGATCTAGCGAT G G A T C C T A C G T A C A TCATGAGATTCAGGATTCATGCTGC - Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forwardlooking statements reflecting the current beliefs and expectations of management and include statements regarding, among other things, future financial performance, expectations and objectives of mana ...